

Prematurely ended - Statement

EudraCT Number:	2021-000613-16
Full title of the study:	CCR1 antagonist treatment in patients hospitalized with COVID-19 A multi-centric, randomized, double-blind, and placebo-controlled clinical phase II trial.
Sponsor-ID:	CATCOVID-v1.2
Sponsor:	Charité – Universitätsmedizin Berlin
Study Contact:	Prof. Dr. med Ulf Landmesser Deutsches Herzzentrum der Charité Klinik für Kardiologie, Angiologie und Intensivmedizin Campus Benjamin Franklin Hindenburgdamm 30 I 12203 Berlin direktion-kardio-cbf@dhzc-charite.de
Product:	BAY 86-5277 60 mg/ml [5-chloro-2-[2-[(2R)-4-[(4-fluorophenyl)methyl]-2-methyl-piperazin-1-yl]-2-oxo-ethoxy]phenyl]urea
Date of early termination:	2023/03/20
Statement:	Due to the inability to recruit a sufficient number of study subjects allowing statistical analysis, only 5 of the planned number of patients (208) could be recruited in the clearly weakened pandemic, no conclusions could be drawn from the study.